IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.

Summary, in English

In breast cancer, high levels of the inflammatory cytokine interleukin-6 (IL-6) have been associated with disease-free survival and treatment resistance. Increased serum levels of IL-6 have been correlated with increased levels of NF-κβ and aromatase expression in adipose tissue. Several IL6 single nucleotide polymorphisms have been associated with breast cancer prognosis, but the impact may differ depending on tumour oestrogen receptor (ER) status. This translational study investigated the association between IL6 genotypes, ER-status, and treatment on the risk of early events among breast cancer patients.

• Author: Andrea Markkula; Maria Simonsson; Christian Ingvar; Carsten Rose; Helena Jernström
• Department/s: Epidemiology and pharmacogenetics; Breastcancer-genetics; Tumor microenvironment; Surgery (Lund); BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2014
• Language: English
• Publication/Series: BMC Cancer
• Volume: 14
• Full text: - 1 MB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25305747?dopt=Abstract; http://dx.doi.org/10.1186/1471-2407-14-759
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Cancer and Oncology
• Status: Published
• Research group: Epidemiology and pharmacogenetics
• ISBN/ISSN/Other: ISSN: 1471-2407